Andrew Lo - 20 Jun 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Reporting relationship: Director
Issuer ticker: BBIO
Reported as of: 20 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2025, 19:13:23 UTC
Prior SEC filing: 16 Jun 2025
Next SEC filing: 19 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew W. Lo, Ph.D.

Key filing fact

Andrew Lo filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 24 Jun 2025.

Key facts

This page summarizes Andrew Lo's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2025, 19:13.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001679076 Primary reporting owner

Lo Andrew

Relationship: Director
Address: C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
Signature: /s/ Andrew W. Lo, Ph.D.
Signature date: 24 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBIO transaction

Common Stock

Award

Transaction value: $0
Shares: +6,589
Change %: +14%
Price: $0.000000
Shares after: 54,688
Date: 20 Jun 2025
Ownership: Direct
Footnotes: F1, F2

BBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 105,583
Date: 20 Jun 2025
Ownership: By Andrew W. Lo and Nancy N. Lo JTWROS

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +8,425
Change %
Price: $0.000000
Shares after: 8,425
Date: 20 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,425
Exercise price: $41.73
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.